<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00504725</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00000895</org_study_id>
    <nct_id>NCT00504725</nct_id>
  </id_info>
  <brief_title>Ketamine In Thoracic Surgery (KITS) Trial</brief_title>
  <acronym>KITS</acronym>
  <official_title>Ketamine In Thoracic Surgery (KITS) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is to demonstrate a reduction in circulating interleukin 6
      levels at 4 and 24 hours after completion of lobectomy (either VATS or open). The null
      hypothesis (H0) is thus that there is no difference in circulating interleukin 6 levels when
      patients are given either ketamine or placebo (0.9% saline in equivalent volume). The
      alternative (two tailed) hypothesis (HA) if the null is disproved is that ketamine leads to
      significantly different levels of interleukin 6 at 4 and 24 hours after completion of
      surgery. We plan to randomize 40 patients to receive either ketamine or placebo, in a block
      of 4 randomization design stratified by whether surgery is performed by VATS or open
      lobectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to be a phase 2 (efficacy) randomized controlled clinical trial of
      ketamine versus placebo in 40 patients undergoing lobectomy by VATS or open approach, at Duke
      University. We selected a single dose regimen of 0.5mg/kg IV ketamine given at induction of
      anesthesia, as this is the dose that previously has been shown to induce maximal suppression
      of the IL-6 response in cardiac surgery.

      We plan to randomize 40 patients to receive either ketamine or placebo, in a block of 4
      randomization design stratified by whether surgery is performed by VATS or open lobectomy. 40
      patients (n=20 per group) will provide 90% power to detect a change in IL 6 of 20 pg/ml from
      a mean of 100 pg/ml at 4 hours, with two tailed alpha = 0.05. Allowing for 10-20% attrition
      we will enroll 50 patients to achieve this sample size. All patients presenting for lobectomy
      either VATS or open will be included. Patients will be screened by review of the preoperative
      surgical schedule posted each day and approached for consent to participate if they do not
      have any exclusion criteria. Patients who are randomized but do not undergo lobectomy for any
      reason will not be included in the analysis of the primary endpoint. Patients who are listed
      for VATS resection but convert to open will be included in the analysis on a per protocol
      basis. The randomization is stratified according to planned approach (VATS vs open), however
      we expect the majority of these cases to be VATS lobectomies.

      Treatment will be by intravenous administration of a single dose of study drug over 5 minutes
      immediately after induction of anesthesia and before surgical incision.

      Patients will be randomized (by sealed envelope) in blocks of 4 to receive ketamine or
      placebo. The randomization will be stratified according to whether the planned surgery is via
      VATS or open (thoracotomy) approach. The study drug will be prepared by the investigational
      pharmacy and provided to the attending anesthesiologist of record for the case. It will
      contain 0.5 mg/kg ketamine for injection by IV bolus over 5 minutes, or as an equivalent
      volume of 0.9% saline. It will be the responsibility of the principal investigator to ensure
      that study drug is administered in a timely fashion, usually by delegation to the attending
      anesthesiologist of record for the case. The anesthetic procedure will be standardized in
      that each patient will receive a total intravenous anesthetic using propofol and an
      intravenous opioid infusion. This anesthetic will be supplemented by an epidural and
      intravenous opioid boluses as needed to control pain.

      Visits by the research team will be performed as follows:

        1. Visit 1 will occur at enrollment, when baseline information (see CRF visit 1) will be
           collected and study consent forms signed.

        2. Visit 2 will occur at induction of anesthesia when study drug will be administered and a
           baseline blood sample of 10ml collected from the patient's arterial line. The blood
           sample will be immediately centrifuged and the serum frozen and stored for subsequent
           analysis.

        3. Visit 3 will occur at 4 hours after completion of surgery when 10 ml blood will be
           collected and CRF visit 3 form will be completed (VAS score and emergence delirium).

        4. Visit 4 will occur at 24 hours after completion of surgery when 10 ml blood will be
           collected and CRF visit 4 form will be completed (VAS score).

        5. The final visit will occur just prior to hospital discharge when CRF visit 5 form will
           be completed (secondary endpoints). Additionally, if the principal investigator is
           informed by either study staff or the clinical team of an adverse event or other
           complication, then the patient will be visited within 24 hours for confirmation of the
           event and ascertainment of whether the event is related to study drug or not. An SAE
           form will be completed and sent to the IRB in line with institutional policy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interleukin Levels at 24 Hours</measure>
    <time_frame>24 Hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-reactive Protein (CRP) Serum Levels</measure>
    <time_frame>24 hours</time_frame>
    <description>The CRP levels were measured 24 hours postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal Pain Scores</measure>
    <time_frame>baseline, 4 hours, 24 hours and at discharge</time_frame>
    <description>Pain scores rated by the subject on a scale of 0 low - 10 high</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single bolus 0.5mg/kg ketamine IV after induction of anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9 % saline bolus of equivalent volume</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Interventional</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% saline</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients presenting for lobectomy either VATS or open.

        Exclusion Criteria:

          -  Patients with myocardial infarction in the previous six months,

          -  Patients with a history of psychotic disorder,

          -  Patients with a history of chronic pain syndrome,

          -  Patients with documented previous allergy to ketamine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andy Shaw, M. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Roytblat L, Talmor D, Rachinsky M, Greemberg L, Pekar A, Appelbaum A, Gurman GM, Shapira Y, Duvdenani A. Ketamine attenuates the interleukin-6 response after cardiopulmonary bypass. Anesth Analg. 1998 Aug;87(2):266-71.</citation>
    <PMID>9706914</PMID>
  </reference>
  <reference>
    <citation>Bartoc C, Frumento RJ, Jalbout M, Bennett-Guerrero E, Du E, Nishanian E. A randomized, double-blind, placebo-controlled study assessing the anti-inflammatory effects of ketamine in cardiac surgical patients. J Cardiothorac Vasc Anesth. 2006 Apr;20(2):217-22. Epub 2006 Mar 9. Retraction in: J Cardiothorac Vasc Anesth. 2014 Oct;28(5):1435.</citation>
    <PMID>16616662</PMID>
  </reference>
  <reference>
    <citation>Tashima T, Yamashita J, Nakano S, Joutsuka T, Hayashi N, Saishoji T, Ogawa M. Comparison of video-assisted minithoracotomy and standard open thoracotomy for the treatment of non-small cell lung cancer. Minim Invasive Ther Allied Technol. 2005;14(3):203-8.</citation>
    <PMID>16754164</PMID>
  </reference>
  <reference>
    <citation>Craig SR, Leaver HA, Yap PL, Pugh GC, Walker WS. Acute phase responses following minimal access and conventional thoracic surgery. Eur J Cardiothorac Surg. 2001 Sep;20(3):455-63.</citation>
    <PMID>11509263</PMID>
  </reference>
  <reference>
    <citation>Yim AP, Wan S, Lee TW, Arifi AA. VATS lobectomy reduces cytokine responses compared with conventional surgery. Ann Thorac Surg. 2000 Jul;70(1):243-7.</citation>
    <PMID>10921716</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2007</study_first_submitted>
  <study_first_submitted_qc>July 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2007</study_first_posted>
  <results_first_submitted>September 29, 2011</results_first_submitted>
  <results_first_submitted_qc>November 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2012</results_first_posted>
  <last_update_submitted>July 18, 2014</last_update_submitted>
  <last_update_submitted_qc>July 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lobectomy</keyword>
  <keyword>VATS</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>Single bolus 0.5mg/kg ketamine IV after induction of anesthesia</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>0.9 % saline bolus of equivalent volume</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20">Prior to unblinding, one subject was discontinued due to elevated CRP levels at baseline.</participants>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>Single bolus 0.5mg/kg ketamine IV after induction of anesthesia</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>0.9 % saline bolus of equivalent volume</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>AGE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" spread="12"/>
                    <measurement group_id="B2" value="66" spread="10"/>
                    <measurement group_id="B3" value="63" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Interleukin Levels at 24 Hours</title>
        <time_frame>24 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Single bolus 0.5mg/kg ketamine IV after induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9 % saline bolus of equivalent volume</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin Levels at 24 Hours</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interleukin-6 (IL-6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245" spread="287"/>
                    <measurement group_id="O2" value="269" spread="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-8 (IL-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="12.6"/>
                    <measurement group_id="O2" value="14.8" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin-10 (IL-10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="4.7"/>
                    <measurement group_id="O2" value="4.9" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL-6</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.39</p_value>
            <p_value_desc>We will use two way ANOVA (looking for effects due to drug and time) with a p value of 0.05 indicative of statistical significance.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL-8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>IL-10</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-reactive Protein (CRP) Serum Levels</title>
        <description>The CRP levels were measured 24 hours postoperatively.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Single bolus 0.5mg/kg ketamine IV after induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9 % saline bolus of equivalent volume</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein (CRP) Serum Levels</title>
          <description>The CRP levels were measured 24 hours postoperatively.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="4.5"/>
                    <measurement group_id="O2" value="9.3" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Verbal Pain Scores</title>
        <description>Pain scores rated by the subject on a scale of 0 low - 10 high</description>
        <time_frame>baseline, 4 hours, 24 hours and at discharge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Single bolus 0.5mg/kg ketamine IV after induction of anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>0.9 % saline bolus of equivalent volume</description>
          </group>
        </group_list>
        <measure>
          <title>Verbal Pain Scores</title>
          <description>Pain scores rated by the subject on a scale of 0 low - 10 high</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.73"/>
                    <measurement group_id="O2" value="0.35" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.1"/>
                    <measurement group_id="O2" value="3.1" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="2.2"/>
                    <measurement group_id="O2" value="2.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.5"/>
                    <measurement group_id="O2" value="1.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.44</p_value>
            <p_value_desc>Baseline Pain Level Score</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <p_value_desc>4 Hour Pain Level Score</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <p_value_desc>24 Hour Pain Level Score</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <p_value_desc>Pain Level Score at Discharge</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>Single bolus 0.5mg/kg ketamine IV after induction of anesthesia</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>0.9 % saline bolus of equivalent volume</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>AF</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>SMALL BOWEL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>RESPIRATORY INSUFFICIENCY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CHEST TUBE PLACEMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Shaw MD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>9192866938</phone>
      <email>andrew.shaw@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

